KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionDividends Paid - CommonDividends Paid - CommonExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares IssuedShares RepurchasedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbbVie (ABBV) Asset Writedowns and Impairment (2018 - 2024)

AbbVie (ABBV) reported Asset Writedowns and Impairment of $4.5 billion for Q4 2024, up 218.58% year-over-year from $1.4 billion in Q1 2024, and up 218.58% on a QoQ basis from $1.4 billion in Q4 2023.

AbbVie (ABBV) has 4 years of Asset Writedowns and Impairment data on file, last reported at $4.5 billion in Q4 2024.

  • Quarterly Asset Writedowns and Impairment rose 218.58% year-over-year to $4.5 billion in Q4 2024, while the trailing twelve-month figure through Dec 2025 was $4.5 billion (changed 0.0% YoY) and the FY2025 annual result came in at $847.0 million, down 81.08% from the prior year.
  • Asset Writedowns and Impairment climbed to $4.5 billion in Q4 2024 per ABBV's latest filing, from $1.4 billion in the prior quarter.
  • Across five years, Asset Writedowns and Impairment topped out at $4.5 billion in Q4 2024 and bottomed at $80.0 million in Q2 2023.
  • The 3-year median for Asset Writedowns and Impairment is $1.1 billion (2022), against an average of $1.6 billion.
  • The widest annual swing landed in 2023, when Asset Writedowns and Impairment jumped 174.55%; it then surged 218.58% in 2024.
  • Tracing ABBV's Asset Writedowns and Impairment over 3 years: stood at $770.0 million in 2022, then soared by 82.47% to $1.4 billion in 2023, then surged by 218.58% to $4.5 billion in 2024.
  • Per Business Quant, the three latest ABBV Asset Writedowns and Impairment figures stand at $4.5 billion (Q4 2024), $1.4 billion (Q4 2023), and $2.1 billion (Q3 2023).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Novartis Ag 107,124,802.25 Bn 107,124,802.25 Bn -
2 Eli Lilly 969.00 Bn 963.72 Bn 16.22 Bn
3 Johnson & Johnson 539.46 Bn 517.41 Bn 15.96 Bn
4 AbbVie 376.92 Bn 367.57 Bn 10.78 Bn
5 Merck 285.00 Bn 279.35 Bn 12.09 Bn
6 Amgen 177.58 Bn 165.55 Bn 5.87 Bn
7 Gilead Sciences 163.22 Bn 155.50 Bn 5.52 Bn
8 Pfizer 145.86 Bn 133.09 Bn -1.21 Bn
9 Bristol Myers Squibb 111.90 Bn 101.44 Bn 8.07 Bn
10 Gsk 88.34 Bn 83.66 Bn -

Historic Data

Download Data 🔒
DateValue
Dec 31, 2024 4.48 Bn
Dec 31, 2024 4.48 Bn
Dec 31, 2023 1.41 Bn
Dec 31, 2023 1.41 Bn
Sep 30, 2023 2.11 Bn
Sep 30, 2023 2.11 Bn
Jun 30, 2023 80.00 Mn
Jun 30, 2023 80.00 Mn
Mar 31, 2023 630.00 Mn
Mar 31, 2023 630.00 Mn
Sep 30, 2022 770.00 Mn
Sep 30, 2022 770.00 Mn
Dec 31, 2018 5.07 Bn
Dec 31, 2018 5.07 Bn